Reuters logo
Novartis to buy U.S.-based biotech CoStim for undisclosed price
February 17, 2014 / 6:30 AM / in 4 years

Novartis to buy U.S.-based biotech CoStim for undisclosed price

ZURICH, Feb 17 (Reuters) - Novartis said it will buy U.S.-based CoStim Pharmaceuticals Inc., a privately held biotechnology company focused on harnessing the immune system to eliminate immune-blocking signals from cancer, for an undisclosed price.

The Swiss drugmaker said the move follows increasing evidence pointing to the role of the immune system in controlling cancer.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below